Healthcare [ 7/13 ] | Biotechnology [ 82/163 ]
NYSE MKT | Common Stock
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins.
It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder.
The company is based in Irvine, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 13, 23 | 1.15 Increased by +2.32 K% | -0.53 Increased by +316.98% |
| Aug 30, 23 | -0.44 Decreased by -918.48% | - |
| May 31, 23 | -0.02 Decreased by -124.13% | - |
| Dec 31, 22 | 0.00 Decreased by -62.50% | - |
| Sep 30, 22 | 0.05 Increased by +106.52% | - |
| Jun 30, 22 | 0.05 Increased by +146.36% | - |
| Mar 31, 22 | 0.08 | - |
| Dec 31, 21 | 0.01 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | N/A Decreased by N/A% | N/A Decreased by N/A% | - - |
| Mar 31, 23 | N/A - | N/A - | - - |
| Dec 31, 22 | 0.00 - | -34.56 M - | Decreased by N/A% - |
| Sep 30, 22 | 0.00 - | -10.44 M - | Decreased by N/A% - |
| Jun 30, 22 | N/A - | N/A - | - - |